Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$2.31 +4.5%	$1.52	$1.03 ▼ $2.57	$462.78M	1.22	1.60 million shs	2.93 million shs
ATOS Atossa Therapeutics	$0.81 -3.1%	$0.75	$0.55 ▼ $1.66	$105.04M	1.01	778,856 shs	429,606 shs
ORKA Oruka Therapeutics	$11.47 +0.3%	$9.75	$5.49 ▼ $31.13	$428.33M	0.25	225,159 shs	123,010 shs
SIGA SIGA Technologies	$6.09 +0.2%	$5.84	$4.95 ▼ $12.83	$435.08M	0.92	728,788 shs	389,503 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	+4.52%	+20.94%	+58.22%	+40.00%	+39.16%
ATOS Atossa Therapeutics	-3.19%	-6.60%	+9.48%	+9.15%	-42.73%
ORKA Oruka Therapeutics	+0.26%	+8.41%	+11.58%	+19.98%	+1,146,999,900.00%
SIGA SIGA Technologies	+0.16%	-0.65%	-4.09%	+12.36%	-20.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	2.2245 of 5 stars	3.7	1.0	2.0	2.5	0.6
ATOS Atossa Therapeutics	1.573 of 5 stars	3.5	0.0	3.2	1.7	0.0
ORKA Oruka Therapeutics	2.7941 of 5 stars	3.6	0.0	3.3	2.5	0.6
SIGA SIGA Technologies	2.2799 of 5 stars	0.0	3.0	2.5	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.33	Buy	$8.67	275.18% Upside
ATOS Atossa Therapeutics	3.00	Buy	$7.13	776.17% Upside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	252.01% Upside
SIGA SIGA Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATOS, SIGA, ATAI, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
5/20/2025	ATAI Atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
5/13/2025	ATAI Atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/21/2025	ATOS Atossa Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25
3/26/2025	ATOS Atossa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/12/2025	ATOS Atossa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/7/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$1.86M	248.41	N/A	N/A	$1.47 per share	1.57
ATOS Atossa Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SIGA SIGA Technologies	$120.33M	3.62	$0.96 per share	6.34	$2.77 per share	2.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.91	N/A	N/A	N/A	N/A	-65.75%	-52.71%	8/12/2025 (Estimated)
ATOS Atossa Therapeutics	-$30.09M	-$0.21	N/A	N/A	N/A	N/A	-35.74%	-33.51%	8/11/2025 (Estimated)
ORKA Oruka Therapeutics	-$5.34M	-$4.51	N/A	N/A	N/A	N/A	-24.96%	-21.22%	8/7/2025 (Estimated)
SIGA SIGA Technologies	$68.07M	$0.67	5.08	4.87	N/A	49.33%	49.06%	38.72%	8/7/2025 (Estimated)

Latest ATOS, SIGA, ATAI, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/13/2025	Q1 2025	ATOS Atossa Therapeutics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/8/2025	Q1 2025	SIGA SIGA Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
3/25/2025	Q4 2024	ATOS Atossa Therapeutics	-$0.0633	-$0.05	+$0.0133	-$0.05	N/A	N/A
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/11/2025	Q4 2024	SIGA SIGA Technologies	N/A	$0.63	N/A	$0.63	N/A	$81.40 million
3/6/2025	Q4 2024	ORKA Oruka Therapeutics	-$0.68	-$0.49	+$0.19	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Therapeutics	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA SIGA Technologies	N/A	N/A	N/A	N/A	N/A

Latest ATOS, SIGA, ATAI, and ORKA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA SIGA Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
ATOS Atossa Therapeutics	N/A	13.30	13.30
ORKA Oruka Therapeutics	N/A	22.89	22.89
SIGA SIGA Technologies	N/A	8.10	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
ATOS Atossa Therapeutics	12.74%
ORKA Oruka Therapeutics	56.44%
SIGA SIGA Technologies	55.40%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
ATOS Atossa Therapeutics	8.70%
ORKA Oruka Therapeutics	22.67%
SIGA SIGA Technologies	1.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	200.34 million	115.45 million	Optionable
ATOS Atossa Therapeutics	8	129.17 million	116.24 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A
SIGA SIGA Technologies	40	71.44 million	70.31 million	Optionable

ATOS, SIGA, ATAI, and ORKA Headlines

Recent News About These Companies

D. E. Shaw & Co. Inc. Sells 87,853 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

May 21, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)

May 17, 2025 | marketbeat.com

We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings

May 16, 2025 | finance.yahoo.com

Undiscovered Gems in the US Market for May 2025

May 16, 2025 | finance.yahoo.com

SIGA Technologies (NASDAQ:SIGA) Issues Quarterly Earnings Results

May 12, 2025 | marketbeat.com

Dimensional Fund Advisors LP Raises Stock Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

May 12, 2025 | marketbeat.com

SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)

May 10, 2025 | finance.yahoo.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call Transcript

May 9, 2025 | msn.com

SIGA Reports Financial Results for Three Months Ended March 31, 2025

May 8, 2025 | globenewswire.com

Investors Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)

May 3, 2025 | marketbeat.com

Calculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

May 2, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors

May 1, 2025 | zacks.com

SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results

May 1, 2025 | globenewswire.com

Chiliz joins SIGA to help drive integrity in sport

April 30, 2025 | en.as.com

Why SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%

April 29, 2025 | aaii.com

Here's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market Today

April 25, 2025 | zacks.com

Siga Technologies Inc. (SIGA) Outperforms Broader Market: What You Need to Know

April 23, 2025 | zacks.com

Siga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should Know

April 17, 2025 | msn.com

3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield (SIGA)

April 16, 2025 | dividendstocks.com

Siga Technologies Inc. (SIGA) Falls More Steeply Than Broader Market: What Investors Need to Know

April 15, 2025 | zacks.com

Siga Technologies Shares Climb on Special Dividend

April 8, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS, SIGA, ATAI, and ORKA Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$2.31 +0.10 (+4.52%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.00 (+0.22%)

As of 08:03 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atossa Therapeutics NASDAQ:ATOS

$0.81 -0.03 (-3.13%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.33%)

As of 08:00 AM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Oruka Therapeutics NASDAQ:ORKA

$11.47 +0.03 (+0.26%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$11.48 +0.01 (+0.13%)

As of 05/28/2025 05:27 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

SIGA Technologies NASDAQ:SIGA

$6.09 +0.01 (+0.16%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$6.14 +0.05 (+0.90%)

As of 08:00 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time